on Biophytis (EPA:ALBPS)
Biophytis Outlines 2025 Strategic Plans
Biophytis, a biotechnology firm focused on age-related diseases, has announced its strategic plans for 2025. Key elements include launching the OBA program for obesity treatment and signing a licensing agreement with Blanver. They are also in talks with a major Chinese pharmaceutical company and have partnered with AskHelpU on ALS.
The company aims to progress the clinical development of BIO101, specifically targeting obesity and sarcopenia. A Phase 2 study for obesity and a Phase 3 SARA program for sarcopenia are in the works. Biophytis sees a significant market opportunity, with obesity projected to hit $100 billion by 2030 and sarcopenia affecting millions in China, Europe, and the US.
CEO Stanislas Veillet highlighted ongoing partnerships to address obesity and sarcopenia, aiming to expand their presence in the Americas, Europe, and Asia.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news